Daniel S. Chen, MD, PhD – Engenuity Life Sciences
Philip D. Greenberg, MD, FAIO – Fred Hutchinson Cancer Research Center
Alexandra Snyder, MD – Generate Biomedicines
Zhen Su, MD, MBA – Marengo Therapeutics
The target audience for this workshop includes basic, translational, and clinical researchers from all work settings with an interest in combination immunotherapy approaches.
The Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments helps SITC to advance the science and application of cancer immunotherapy by providing relevant and engaging content to basic, translational, and clinical researchers. This Workshop will explore how the underlying biology of combination therapies and how those combinations may change and overcome specific mechanisms of resistance. The Workshop also aims to discuss provocative questions concerning novel combination immunotherapeutic development armed with a deeper biological understanding of how rational combinations and sequences of therapies can overcome specific resistance mechanisms, attendees will be equipped to design effective clinical trials leading to better patient outcomes.
At the conclusion of this activity, participants should be able to:
- Understand tumor biological factors that limit and/or reduce immunotherapy efficacy and inform patient selection strategies
- Detail combination immunotherapy approaches designed to overcome tumor biological mechanisms limiting anti-cancer immunity
- Relate principles of reverse translation to emerging concepts behind novel combination development
- Use translational analyses, including high dimensional data, to understand what patient populations should be pursued in disease setting
- Apply information learned from previous trials to develop the next generation of more effective combination therapies and strategies
Combination Therapy: Applying Learnings from Past Successes and Failures to Future Treatments is supported in part by grants from Alkermes, Inc., Bristol Myers Squibb, Genmab US, Inc, Incyte Corporation, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD) (as of October 13, 2022)